Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1121-1129

  Duan, Zhenfeng ^a   Choy, Edwin ^a   Jimeno, Jose Maria ^b   Cuevas, Carmen Del Maria ^b   Mankin, Henry J ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PharmaMar USA Inc   (United States)

Author keywords

ABCB1 MDR1; ET 743; Multi drug resistance gene 1; PM00104; Yondelis; Zalypsis

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PM 00104; SMALL INTERFERING RNA; TRABECTEDIN; UNCLASSIFIED DRUG; ZALYPSIS;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; OSTEOSARCOMA CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DIOXOLES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEINS; TETRAHYDROISOQUINOLINES;

EID: 63949087284     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0843-2     Document Type: Article

References (29)

1. ML Amador J Jimeno L Paz-Ares H Cortes-Funes M Hidalgo 2003 Progress in the development and acquisition of anticancer agents from marine sources Ann Oncol 14 1607 1615
2. JH Beumer T Buckle M Ouwehand NE Franke L Lopez-Lazaro JH Schellens JH Beijnen O van Tellingen 2007 Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype Invest New Drugs 25 1 7
3. J Carmichael WG DeGraff AF Gazdar JD Minna JB Mitchell 1987 Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res 47 936 942
4. NJ Carter SJ Keam 2007 Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer Drugs 67 2257 2276
5. TC Cheng G Manorek G Samimi X Lin CC Berry SB Howell 2006 Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells Cancer Chemother Pharmacol 58 384 395
6. G Damia S Silvestri L Carrassa L Filiberti GT Faircloth G Liberi M Foiani M D'Incalci 2001 Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways Int J Cancer 92 583 588
7. Z Duan R Foster KA Brakora RZ Yusuf MV Seiden 2006 GBP1 overexpression is associated with a paclitaxel resistance phenotype Cancer Chemother Pharmacol 57 25 33
8. Z Duan DE Lamendola Y Duan RZ Yusuf MV Seiden 2005 Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines Cancer Chemother Pharmacol 55 277 285
9. E Erba D Bergamaschi L Bassano S Ronzoni G Di Liberti I Muradore S Vignati G Faircloth J Jimeno M D'Incalci 2000 Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743) Br J Cancer 82 1732 1739
10. G Faircloth C Cuevas 2006 Kahalalide F and ES285: potent anticancer agents from marine molluscs Prog Mol Subcell Biol 43 363 379
11. N Feller HJ Broxterman DC Wahrer HM Pinedo 1995 ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion FEBS Lett 368 385 388
12. R Garcia-Carbonero JG Supko RG Maki J Manola DP Ryan D Harmon TA Puchalski G Goss MV Seiden A Waxman MT Quigley T Lopez MA Sancho J Jimeno C Guzman GD Demetri 2005 Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study J Clin Oncol 23 5484 5492
13. ML Hensley R Maki E Venkatraman G Geller M Lovegren C Aghajanian P Sabbatini W Tong R Barakat DR Spriggs 2002 Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol 20 2824 2831
14. AB Herrero C Martin-Castellanos E Marco F Gago S Moreno 2006 Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin Cancer Res 66 8155 8162
15. A Kanzaki Y Takebayashi XQ Ren H Miyashita S Mori S Akiyama Y Pommier 2002 Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743 Mol Cancer Ther 1 1327 1334
16. CN Krasner DS McMeekin S Chan PS Braly FG Renshaw S Kaye DM Provencher S Campos ME Gore 2007 A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618 1624
17. A Le Cesne JY Blay I Judson A Van Oosterom J Verweij J Radford P Lorigan S Rodenhuis I Ray-Coquard S Bonvalot F Collin J Jimeno E Di Paola M Van Glabbeke OS Nielsen 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol 23 576 584
18. M Lourda IP Trougakos ES Gonos 2007 Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein J Int J Cancer 120 611 622
19. MC Manara S Perdichizzi M Serra R Pierini S Benini CM Hattinger A Astolfi R Bagnati M D'Incalci P Picci K Scotlandi 2005 The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71 Int J Oncol 27 1605 1616
20. KL Rinehart 2000 Antitumor compounds from tunicates Med Res Rev 20 1 27
21. KL Rinehart TG Holt NL Fregeau PA Keifer GR Wilson TJ Perun Jr R Sakai AG Thompson JG Stroh LS Shield 1990 Bioactive compounds from aquatic and terrestrial sources J Nat Prod 53 771 792
22. DD Ross W Yang LV Abruzzo WS Dalton E Schneider H Lage M Dietel L Greenberger SP Cole LA Doyle 1999 Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines J Natl Cancer Inst 91 429 433
23. P Schoffski P Wolter P Clement R Sciot I De Wever A Wozniak C Stefan H Dumez 2007 Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma Future Oncol 3 381 392
24. HT See JJ Kavanagh W Hu RC Bast 2003 Targeted therapy for epithelial ovarian cancer: current status and future prospects Int J Gynecol Cancer 13 701 734
25. L Shao J Kasanov FJ Hornicek T Morii G Fondren L Weissbach 2003 Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations Biochem Pharmacol 66 2381 2395
26. DG Soares AE Escargueil V Poindessous A Sarasin A de Gramont D Bonatto JA Henriques AK Larsen 2007 Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 Proc Natl Acad Sci USA 104 13062 13067
27. G Valoti MI Nicoletti A Pellegrino J Jimeno H Hendriks M D'Incalci G Faircloth R Giavazzi 1998 Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts Clin Cancer Res 4 1977 1983
28. J Yin P Aviles W Lee C Ly MJ Guillen S Munt C Cuevas G Faircloth 2005 Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma Rapid Commun Mass Spectrom 19 689 695
29. RZ Yusuf Z Duan DE Lamendola RT Penson MV Seiden 2003 Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation Curr Cancer Drug Targets 3 1 19